Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it
Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it
Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it
Submitted by
admin
on May 3, 2017 - 10:52am
Source:
Endpoints
News Tags:
Magenta Therapeutics
Novartis
stem cells
HSC835
Headline:
Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it
Do Not Allow Advertisers to Use My Personal information
